Tonix Pharmaceuticals Holding Corp. (TNXP) Financials

TNXP Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 254.1 million 31.8 million
March 31, 2026 257.9 million 30.8 million
Dec. 31, 2025 277.2 million 32.0 million
Sept. 30, 2025 252.4 million 21.3 million

TNXP Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -42.8 million 2.3 million
March 31, 2026 -44.0 million 2.0 million
Dec. 31, 2025 -41.5 million 1.8 million
Sept. 30, 2025 -31.5 million 1.8 million

TNXP Net Income

No data available :(

TNXP Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 176.2 million - 1.3 million
March 31, 2026 185.5 million 1.1 million 162000
Dec. 31, 2025 207.6 million - 1.2 million
Sept. 30, 2025 190.1 million - 425000

TNXP Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 16.6 million
March 31, 2026 13.7 million
Dec. 31, 2025 8.5 million
Sept. 30, 2025 8.9 million

TNXP Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 587000 19.4 million 36.0 million -
March 31, 2026 1.7 million 18.2 million 28.1 million -
Dec. 31, 2025 1.9 million 16.9 million 35.2 million -
Sept. 30, 2025 1.0 million 9.3 million 25.7 million -

TNXP Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 13.5 million 703000
March 31, 2026 6.9 million 2.1 million
Dec. 31, 2025 5.4 million 1.5 million
Sept. 30, 2025 3.3 million 1.4 million

TNXP

Price: $12.68

52 week price:
9.40
69.97

Payout Ratio Range:
-30.09%
-2.65%

Earnings Per Share: -13.09 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 943700

Ebitda: -5.8 million

Market Capitalization: 218.0 million

Links: